In a filing, Relay Therapeutics Inc revealed its insider Rahmer Peter unloaded Company’s shares for reported $57864.0 on Jul 29 ’25. In the deal valued at $3.68 per share,15,724 shares were sold. As a result of this transaction, Rahmer Peter now holds 377,998 shares worth roughly $1.38 million.
Then, Rahmer Peter sold 1,359 shares, generating $5,083 in total proceeds. Upon selling the shares at $3.74, the insider now owns 393,722 shares.
Before that, Catinazzo Thomas sold 18,380 shares. Relay Therapeutics Inc shares valued at $67,638 were divested by the Chief Financial Officer at a price of $3.68 per share. As a result of the transaction, Catinazzo Thomas now holds 335,295 shares, worth roughly $1.22 million.
Wells Fargo initiated its Relay Therapeutics Inc [RLAY] rating to an Equal weight in a research note published on April 17, 2025; the price target was $4. A number of analysts have revised their coverage, including Jefferies’s analysts, who increased its forecast for the stock in early September from “a Hold” to “a Buy”. Oppenheimer revised its rating on September 10, 2024. It rated RLAY as “a Perform” which previously was an “an Outperform”.
Price Performance Review of RLAY
On Monday, Relay Therapeutics Inc [NASDAQ:RLAY] saw its stock jump 8.63% to $3.65. Over the last five days, the stock has lost -1.35%. Relay Therapeutics Inc shares have fallen nearly -55.60% since the year began. Nevertheless, the stocks have fallen -11.41% over the past one year.
How much short interest is there in Relay Therapeutics Inc?
A steep rise in short interest was recorded in Relay Therapeutics Inc stocks on 2025-07-15, dropping by -1.0 million shares to a total of 21.52 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 22.52 million shares. There was a decline of -4.67%, which implies that there is a negative sentiment for the stock.
